Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy

Rouvas, Alexandros; Stavrakas, Panagiotis; Theodossiadis, Panagiotis; Stamatiou, Polyxeni; Milia, Maria Grazia; Giannakaki, Emmanuela; Datseris, Ioannis

doi:10.5301/ejo.5000051

Cited by 42 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45,46 In contrast, in our study, only one patient was naive of medical care, whereas the rest of the patients failed to respond to other treatment modalities before being included in this trial. Three of our patients had a past medical history of IVB, and patient no.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Therapeutic benefit of melatonin in refractory central serous chorioretinopathy

Gramajo

Marquez

Torres

et al. 2015

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 70%

“…Five patients with chronic CSCR served as a control group. The mean age of control patients was 44 years old (range, [34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53], with the woman/man ratio being 1 : 4. The number of right and left eyes studied was also similar (3 right eyes and 2 left eyes).…”

Section: Resultsmentioning

confidence: 99%

Therapeutic benefit of melatonin in refractory central serous chorioretinopathy

Gramajo

Marquez

Torres

et al. 2015

Eye

View full text Add to dashboard Cite

“…Thus, modifications of this modality were designed, such as half-dose PDT and low-fluence PDT. These modalities have shown favorable results in treating CSC [11,14]. Half-dose PDT, which reduces the amount of verteporfin administration, and low-fluence PDT, which reduces the laser power, have been designed and widely adopted.…”

Section: Discussionmentioning

confidence: 99%

Comparative Study of Subjects with Chronic Central Serous Chorioretinopathy Undergoing Half-Dose or Time-Reduced Photodynamic Therapy

Kang

2016

J Retin

View full text Add to dashboard Cite

Purpose:To compare the clinical outcomes of reduced fluence (time-reduced) photodynamic therapy (PDT) and half-dose PDT in treating chronic central serous chorioretinopathy (CSC). Methods: Medical records of patients who underwent half-dose or reduced fluence PDT for chronic CSC were reviewed. The clinical outcomes of 34 eyes that underwent half-dose PDT and 39 eyes that underwent reduced fluence PDT were compared. Results: Six months after treatment, complete absorption of subretinal fluid was observed in 29 of 34 eyes (85.3%) in the half-dose PDT group and 36 of 39 eyes (92.3%) in the reduced fluence PDT group (p = 0.46). Twenty-one of 34 (61.8%) eyes in the half-dose PDT group and 27 of 39 (69.2%) eyes in the reduced fluence PDT group achieved visual improvement of more than one line in the Snellen chart (p = 0.62). Focal retinal pigment epithelium degeneration after treatment was noted in 7 of 27 eyes (25.9%) in the half-dose PDT group and 10 of 30 (33.3%) eyes in the reduced fluence PDT group (p = 0.58). Conclusions: Reduced fluence PDT showed a favorable outcome, similar to that of half-dose PDT, in treating chronic CSC. Because of its convenient preparation and application, reduced fluence (low-fluence) PDT might be an alternative treatment modality in treating chronic CSC.

show abstract

“…Long-term follow-up to an average of 20 months after halfdose verteporfin PDT in a retrospective analysis of 29 eyes showed 100% resolution of subretinal fluid, with no adverse effects. 74 When compared with focal laser photocoagulation in a nonrandomized comparative study of 26 eyes, there was faster resolution of subretinal fluid and return to BCVA with half-dose PDT, but by 3 months, there was no difference between treatments. 75 ICGA, indocyanine green angiography; PDT, photodynamic therapy; VA, visual acuity.…”

Section: Pdtmentioning

confidence: 99%

Diagnosis and interventions for central serous chorioretinopathy: review and update

Quin

Liew

et al. 2012

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Most acute cases of central serous chorioretinopathy resolve spontaneously with minimal visual impairment. The small percentage of eyes developing chronic or recurrent disease that do warrant treatment is often difficult to control. Emergent investigations and treatments have added to the established options available to manage these cases. Optical coherence tomography has proved valuable for both imaging subtle fundoscopic findings and monitoring disease progression. Fluorescein angiography aids identification of pigment epithelial leaks and targets the use of argon laser treatment if outside the fovea. Fluorescein angiography also assists differentiation from other choroidal pathologies such as choroidal neovascularization and polypoidal choroidal vasculopathy. Where the diagnosis is uncertain, indocyanine green angiography can demonstrate classic midphase hyperpermeability. This is also useful to guide the application of photodynamic therapy. Newer treatments such as intravitreal anti-vascular endothelial growth factor are as yet unproven.

show abstract

Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy

Abstract: The long-term results of this study further support the safety and effectiveness of safety-enhanced PDT with half dose of verteporfin for the treatment of chronic CSC.

Cited by 42 publications

References 20 publications

Therapeutic benefit of melatonin in refractory central serous chorioretinopathy

Therapeutic benefit of melatonin in refractory central serous chorioretinopathy

Comparative Study of Subjects with Chronic Central Serous Chorioretinopathy Undergoing Half-Dose or Time-Reduced Photodynamic Therapy

Diagnosis and interventions for central serous chorioretinopathy: review and update

Contact Info

Product

Resources

About